Should I buy or sell NeuroPace stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NPCE shares. View NPCE analyst ratings or view top-rated stocks .

What is NeuroPace's stock price target for 2024?

5 brokerages have issued 12 month price objectives for NeuroPace's shares. Their NPCE share price targets range from $9.00 to $11.00. On average, they expect the company's share price to reach $9.60 in the next year. This suggests a possible upside of 15.5% from the stock's current price. View analysts price targets for NPCE or view top-rated stocks among Wall Street analysts .

How have NPCE shares performed in 2023?

NeuroPace's stock was trading at $1.49 at the start of the year. Since then, NPCE stock has increased by 457.7% and is now trading at $8.31. View the best growth stocks for 2023 here .

Are investors shorting NeuroPace?

NeuroPace saw a decrease in short interest in November. As of November 15th, there was short interest totaling 151,000 shares, a decrease of 61.8% from the October 31st total of 395,600 shares. Based on an average daily trading volume, of 69,000 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.4% of the company's shares are sold short. View NeuroPace's Short Interest .

When is NeuroPace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024. View our NPCE earnings forecast .

How were NeuroPace's earnings last quarter?

NeuroPace, Inc. (NASDAQ:NPCE) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.11. The firm earned $16.43 million during the quarter, compared to analyst estimates of $14.23 million. NeuroPace had a negative net margin of 62.96% and a negative trailing twelve-month return on equity of 151.83%.

When did NeuroPace IPO?

(NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

Who are NeuroPace's major shareholders?

NeuroPace's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Morgan Stanley (9.13%), FMR LLC (2.69%), Kent Lake Capital LLC (2.19%), EAM Investors LLC (0.54%), Barclays PLC (0.04%) and Citigroup Inc. (0.01%). Insiders that own company stock include Accelmed Partners Ii LP, Frank M Fischer , Irina Ridley , Ltd Kck and Orbimed Advisors Llc. View institutional ownership trends .

How do I buy shares of NeuroPace?

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

NeuroPace Stock Price, News & Analysis (NASDAQ:NPCE)

$8.31

+0.18 (+2.21%)

(As of 12/5/2023 ET)

Compare

Today's Range: $7.69
▼
$8.41
50-Day Range: $5.90
▼
$9.73
52-Week Range: $1.22
▼
$9.73

Volume: 63,265 shs
Average Volume: 45,133 shs
Market Capitalization: $218.42 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.60

NeuroPace MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 15.5% Upside
$9.60 Price Target
Short Interest: Healthy
1.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.15
Based on 5 Articles This Week
Insider Trading: Selling Shares
$191,658 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.38) to ($1.16) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

345th out of 948 stocks

Surgical & Medical Instruments Industry

36th out of 82 stocks

2.3

Analyst's Opinion

Consensus Rating
NeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.60, NeuroPace has a forecasted upside of 15.5% from its current price of $8.31.
Amount of Analyst Coverage
NeuroPace has only been the subject of 4 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.40% of the float of NeuroPace has been sold short.
Short Interest Ratio / Days to Cover
NeuroPace has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NeuroPace has recently decreased by 61.83%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
NeuroPace does not currently pay a dividend.
Dividend Growth
NeuroPace does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NPCE.

2.1

News and Social Media Coverage

News Sentiment
NeuroPace has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for NeuroPace this week, compared to 1 article on an average week.
Search Interest
1 people have searched for NPCE on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added NeuroPace to their MarketBeat watchlist in the last 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $191,658.00 in company stock.
Percentage Held by Insiders
27.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
67.69% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for NeuroPace are expected to grow in the coming year, from ($1.38) to ($1.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NeuroPace is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NeuroPace is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NeuroPace has a P/B Ratio of 5.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About NeuroPace Stock (NASDAQ:NPCE)

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

NPCE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NPCE Stock News Headlines

December 5, 2023 | americanbankingnews.com

NeuroPace (NASDAQ:NPCE) Price Target Raised to $9.00 at Morgan Stanley

December 1, 2023 | finance.yahoo.com

NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting

December 6, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

November 21, 2023 | finance.yahoo.com

NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference

November 11, 2023 | msn.com

Cantor Fitzgerald Initiates Coverage of NeuroPace (NPCE) with Overweight Recommendation

November 10, 2023 | markets.businessinsider.com

Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive Position

November 7, 2023 | finance.yahoo.com

NeuroPace, Inc. (NASDAQ:NPCE) Q3 2023 Earnings Call Transcript

November 7, 2023 | finanznachrichten.de

NeuroPace, Inc.: NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

December 6, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 6, 2023 | msn.com

NeuroPace GAAP EPS of -$0.28 beats by $0.13, revenue of $16.4M beats by $2.18M

November 6, 2023 | finance.yahoo.com

NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

November 6, 2023 | finance.yahoo.com

NeuroPace Inc (NPCE) Reports 47% YoY Revenue Growth in Q3 2023, Raises Full Year Revenue Guidance

November 2, 2023 | finance.yahoo.com

NeuroPace, Inc.'s (NASDAQ:NPCE) top owners are private equity firms with 54% stake, while 21% is held by institutions

October 18, 2023 | finanznachrichten.de

NeuroPace, Inc.: NeuroPace Announces RNS System Enhancements Designed to Streamline Care

October 17, 2023 | finance.yahoo.com

NeuroPace Announces RNS System Enhancements Designed to Streamline Care

October 16, 2023 | finance.yahoo.com

NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023

October 5, 2023 | benzinga.com

NeuroPace 10% Owner Trades $75K In Company Stock

October 5, 2023 | finance.yahoo.com

OrbiMed Advisors LLC Reduces Stake in NeuroPace Inc

September 20, 2023 | finance.yahoo.com

NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference

August 25, 2023 | msn.com

Morgan Stanley Upgrades NeuroPace (NPCE)

August 24, 2023 | finance.yahoo.com

NeuroPace to Participate in Upcoming Investor Conferences

August 13, 2023 | finance.yahoo.com

Rainbows and Unicorns: NeuroPace, Inc. (NASDAQ:NPCE) Analysts Just Became A Lot More Optimistic

August 9, 2023 | finanznachrichten.de

NeuroPace, Inc.: NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

August 8, 2023 | finance.yahoo.com

NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

July 19, 2023 | finance.yahoo.com

NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market

July 18, 2023 | finance.yahoo.com

NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023

June 29, 2023 | finanznachrichten.de

NeuroPace, Inc.: NeuroPace Announces CEO Transition

See More Headlines

Receive NPCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/07/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NPCE
CUSIP: N/A
CIK: 1528287
Web: www.neuropace.com
Phone: 650-237-2700
Fax: N/A
Employees: 169
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.60
High Stock Price Target: $11.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +15.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,080,000.00
Net Margins: -62.96%
Pretax Margin: -62.96%
Return on Equity: -151.83%
Return on Assets: -35.93%

Debt

Debt-to-Equity Ratio: 3.42
Current Ratio: 6.55
Quick Ratio: 5.79

Sales & Book Value

Annual Sales: $60.20 million
Price / Sales: 3.63
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.40 per share
Price / Book: 5.94

Miscellaneous

Outstanding Shares: 26,284,000
Free Float: 19,056,000
Market Cap: $218.42 million
Optionable: Not Optionable
Beta: 2.13

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Ms. Irina Ridley (Age 37)
Chief Legal Officer & Corporate Secretary
Comp: $499.31k
Dr. Martha J. Morrell (Age 66)
Chief Medical Officer
Comp: $555.87k
Mr. Joel D. Becker (Age 55)
CEO & Director
Ms. Rebecca L. Kuhn (Age 62)
CFO, VP of Finance & Administration and Assistant Secretary
Comp: $440.92k
Ms. Kelley Nicholas
Vice President of Sales
Ms. Irene Thomas (Age 54)
Vice President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NPCE Stock Analysis - Frequently Asked Questions

Should I buy or sell NeuroPace stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NPCE shares.
View NPCE analyst ratings or view top-rated stocks.
What is NeuroPace's stock price target for 2024?: 5 brokerages have issued 12 month price objectives for NeuroPace's shares. Their NPCE share price targets range from $9.00 to $11.00. On average, they expect the company's share price to reach $9.60 in the next year. This suggests a possible upside of 15.5% from the stock's current price.
View analysts price targets for NPCE or view top-rated stocks among Wall Street analysts.
How have NPCE shares performed in 2023?: NeuroPace's stock was trading at $1.49 at the start of the year. Since then, NPCE stock has increased by 457.7% and is now trading at $8.31.
View the best growth stocks for 2023 here.
Are investors shorting NeuroPace?: NeuroPace saw a decrease in short interest in November. As of November 15th, there was short interest totaling 151,000 shares, a decrease of 61.8% from the October 31st total of 395,600 shares. Based on an average daily trading volume, of 69,000 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.4% of the company's shares are sold short.
View NeuroPace's Short Interest.
When is NeuroPace's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our NPCE earnings forecast.

How were NeuroPace's earnings last quarter?: NeuroPace, Inc. (NASDAQ:NPCE) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.11. The firm earned $16.43 million during the quarter, compared to analyst estimates of $14.23 million. NeuroPace had a negative net margin of 62.96% and a negative trailing twelve-month return on equity of 151.83%.
When did NeuroPace IPO?: (NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.
Who are NeuroPace's major shareholders?: NeuroPace's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Morgan Stanley (9.13%), FMR LLC (2.69%), Kent Lake Capital LLC (2.19%), EAM Investors LLC (0.54%), Barclays PLC (0.04%) and Citigroup Inc. (0.01%). Insiders that own company stock include Accelmed Partners Ii LP, Frank M Fischer, Irina Ridley, Ltd Kck and Orbimed Advisors Llc.
View institutional ownership trends.
How do I buy shares of NeuroPace?: Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NPCE) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial